Lexeo Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 58
- Market Cap
- $365.3M
- Website
- http://www.lexeotx.com
- Introduction
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
- Conditions
- PKP2-ARVCArrhythmogenic CardiomyopathyPKP2-ACM
- Interventions
- Genetic: LX2020
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Lexeo Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT06109181
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
- Conditions
- Friedreich AtaxiaCardiomyopathy, Secondary
- Interventions
- Genetic: Low dose LX2006Genetic: Mid Dose LX2006Genetic: High Dose LX2006
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Lexeo Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT05445323
- Locations
- 🇺🇸
Ataxia Center and HD Center of Excellence, University of California, Los Angeles, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Biological: LX1001
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Lexeo Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT05400330
- Locations
- 🇺🇸
PPD- Orlando Research Unit, Orlando, Florida, United States
🇺🇸Duke University, Durham, North Carolina, United States
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
- Conditions
- Early Onset Alzheimer DiseaseAlzheimer Disease
- Interventions
- Biological: LX1001
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Lexeo Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT03634007
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸K2 Medical Research, Maitland, Florida, United States
🇺🇸PPD- Orlando Research Unit, Orlando, Florida, United States